{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T12:27:10Z","timestamp":1743856030221,"version":"3.38.0"},"reference-count":56,"publisher":"Spandidos Publications","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncol Lett"],"DOI":"10.3892\/ol.2025.14933","type":"journal-article","created":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T13:14:17Z","timestamp":1739452457000},"source":"Crossref","is-referenced-by-count":1,"title":["Pembrolizumab as an effective treatment for diffuse malignant peritoneal mesothelioma with long\u2011term survival: A case report and literature review"],"prefix":"10.3892","volume":"29","author":[{"given":"Chongxiang","family":"Xue","sequence":"first","affiliation":[{"name":"School of Clinical Medicine, Beijing University of Chinese Medicine, Beijing 100029, P.R.\u00a0China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhe","family":"Dong","sequence":"additional","affiliation":[{"name":"Center for Coronary Artery Disease, Division of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, P.R.\u00a0China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kexin","family":"Tan","sequence":"additional","affiliation":[{"name":"Department of Traditional Chinese Medicine\/Integrative Medicine, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University\/Hunan Cancer Hospital, Changsha, Hunan 410006, P.R.\u00a0China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xu","family":"Zhang","sequence":"additional","affiliation":[{"name":"Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong 250117, P.R.\u00a0China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yixuan","family":"Yu","sequence":"additional","affiliation":[{"name":"Intensive Care Unit, Department of Respiratory and Critical Care Medicine, The Fourth Affiliated Hospital of Zhejiang University School of Medicine, Yiwu, Zhejiang 322000, P.R.\u00a0China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuo","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Integrative Oncology, China\u2011Japan Friendship Hospital, Beijing 100029, P.R.\u00a0China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiabin","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Integrative Oncology, China\u2011Japan Friendship Hospital, Beijing 100029, P.R.\u00a0China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huijuan","family":"Cui","sequence":"additional","affiliation":[{"name":"Department of Integrative Oncology, China\u2011Japan Friendship Hospital, Beijing 100029, P.R.\u00a0China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2025,2,13]]},"reference":[{"key":"key20250312100340_b1-ol-29-4-14933","doi-asserted-by":"publisher","first-page":"236","DOI":"10.21037\/atm.2017.03.96","article-title":"Malignant peritoneal mesothelioma: A review","volume":"5","author":"Kim","year":"2017","journal-title":"Ann Transl Med"},{"key":"key20250312100340_b2-ol-29-4-14933","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1007\/s10552-009-9328-9","article-title":"Pleural and peritoneal mesotheliomas in SEER: Age effects and temporal trends, 1973\u20132005","volume":"20","author":"Moolgavkar","year":"2009","journal-title":"Cancer Causes Control"},{"key":"key20250312100340_b3-ol-29-4-14933","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1093\/annonc\/mdl345","article-title":"Epidemiology of peritoneal mesothelioma: A review","volume":"18","author":"Boffetta","year":"2007","journal-title":"Ann Oncol"},{"key":"key20250312100340_b4-ol-29-4-14933","doi-asserted-by":"publisher","first-page":"S100","DOI":"10.21037\/tlcr.2019.11.23","article-title":"Immunotherapy for mesothelioma: A critical review of current clinical trials and future perspectives","volume":"9","author":"Gray","year":"2020","journal-title":"Transl Lung Cancer Res"},{"key":"key20250312100340_b5-ol-29-4-14933","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/978-1-4613-1247-5_23","article-title":"Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis","volume":"82","author":"Jacquet","year":"1996","journal-title":"Cancer Treat Res"},{"key":"key20250312100340_b6-ol-29-4-14933","doi-asserted-by":"publisher","first-page":"e143","DOI":"10.1016\/S1470-2045(17)30074-8","article-title":"iRECIST: Guidelines for response criteria for use in trials testing immunotherapeutics","volume":"18","author":"Seymour","year":"2017","journal-title":"Lancet Oncol"},{"key":"key20250312100340_b7-ol-29-4-14933","doi-asserted-by":"publisher","first-page":"2782590","DOI":"10.1155\/2017\/2782590","article-title":"Life expectancy in pleural and peritoneal mesothelioma","volume":"2017","author":"Shavelle","year":"2017","journal-title":"Lung Cancer Int"},{"key":"key20250312100340_b8-ol-29-4-14933","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1177\/030089160308900307","article-title":"Clinical presentation of peritoneal mesothelioma","volume":"89","author":"Acherman","year":"2003","journal-title":"Tumori"},{"key":"key20250312100340_b9-ol-29-4-14933","first-page":"246","article-title":"Diffuse malignant peritoneal mesothelioma with paraneoplastic syndrome: A case report and literature review","volume":"49","author":"Su","year":"2022","journal-title":"Cancer Res Prev Treat"},{"key":"key20250312100340_b10-ol-29-4-14933","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1245\/s10434-015-4962-9","article-title":"The role of Ki-67 and pre-cytoreduction parameters in selecting diffuse malignant peritoneal mesothelioma (DMPM) patients for cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC)","volume":"23","author":"Kusamura","year":"2016","journal-title":"Ann Surg Oncol"},{"key":"key20250312100340_b11-ol-29-4-14933","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1111\/imj.14936","article-title":"Osteopontin, GLUT1 and Ki-67 expression in malignant peritoneal mesothelioma: Prognostic implications","volume":"51","author":"Liu","year":"2021","journal-title":"Intern Med J"},{"key":"key20250312100340_b12-ol-29-4-14933","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.clcc.2022.08.001","article-title":"Response to ipilimumab and nivolumab in a patient with malignant peritoneal mesothelioma","volume":"21","author":"Rizzolo","year":"2022","journal-title":"Clin Colorectal Cancer"},{"key":"key20250312100340_b13-ol-29-4-14933","doi-asserted-by":"publisher","first-page":"e34349","DOI":"10.1097\/MD.0000000000034349","article-title":"Metachronous double primary malignant tumors with nasopharyngeal carcinoma and diffuse malignant peritoneal mesothelioma accompanied with paraneoplastic syndromes treated with nivolumab: A case report","volume":"102","author":"Tang","year":"2023","journal-title":"Medicine (Baltimore)"},{"key":"key20250312100340_b14-ol-29-4-14933","doi-asserted-by":"publisher","first-page":"1611577","DOI":"10.3389\/pore.2023.1611577","article-title":"Clinical and pathological observation of conversion therapy for malignant peritoneal mesothelioma: A case report and literature review","volume":"29","author":"Deng","year":"2024","journal-title":"Pathol Oncol Res"},{"key":"key20250312100340_b15-ol-29-4-14933","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1001\/jamaoncol.2017.2918","article-title":"Identification of ALK rearrangements in malignant peritoneal mesothelioma","volume":"4","author":"Hung","year":"2018","journal-title":"JAMA Oncol"},{"key":"key20250312100340_b16-ol-29-4-14933","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.humpath.2019.02.001","article-title":"Tumor PD-L1 expression in malignant pleural and peritoneal mesothelioma by Dako PD-L1 22C3 pharmDx and Dako PD-L1 28-8 pharmDx assays","volume":"87","author":"Chapel","year":"2019","journal-title":"Hum Pathol"},{"key":"key20250312100340_b17-ol-29-4-14933","first-page":"e52716","article-title":"A complete response to pembrolizumab in malignant peritoneal mesothelioma: A case report","volume":"16","author":"Bairos Menezes","year":"2024","journal-title":"Cureus"},{"key":"key20250312100340_b18-ol-29-4-14933","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.canep.2017.10.003","article-title":"Differences between peritoneal and pleural mesothelioma in Lombardy, Italy","volume":"51","author":"Mensi","year":"2017","journal-title":"Cancer Epidemiol"},{"key":"key20250312100340_b19-ol-29-4-14933","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1038\/sj.onc.1209809","article-title":"Molecular profiling of malignant peritoneal mesothelioma identifies the ubiquitin-proteasome pathway as a therapeutic target in poor prognosis tumors","volume":"26","author":"Borczuk","year":"2007","journal-title":"Oncogene"},{"key":"key20250312100340_b20-ol-29-4-14933","doi-asserted-by":"publisher","first-page":"2970","DOI":"10.1158\/0008-5472.CAN-05-3907","article-title":"Global gene expression profiling of pleural mesotheliomas: overexpression of aurora kinases and P16\/CDKN2A deletion as prognostic factors and critical evaluation of microarray-based prognostic prediction","volume":"66","author":"L\u00f3pez-R\u00edos","year":"2006","journal-title":"Cancer Res"},{"key":"key20250312100340_b21-ol-29-4-14933","doi-asserted-by":"publisher","first-page":"2715","DOI":"10.1111\/1759-7714.15022","article-title":"Chinese expert consensus on the diagnosis and treatment of malignant pleural mesothelioma","volume":"14","author":"Wang","year":"2023","journal-title":"Thorac Cancer"},{"key":"key20250312100340_b22-ol-29-4-14933","article-title":"Mesothelioma","volume-title":"Peritoneal, Version 1","author":"National Comprehensive Cancer Network (NCCN)","year":"2021"},{"key":"key20250312100340_b23-ol-29-4-14933","doi-asserted-by":"publisher","first-page":"e21094","DOI":"10.1200\/JCO.2020.38.15_suppl.e21094","article-title":"Real-world outcomes of pembrolizumab in peritoneal mesothelioma","volume":"38","author":"Marmarelis","year":"2020","journal-title":"J Clin Oncol"},{"key":"key20250312100340_b24-ol-29-4-14933","doi-asserted-by":"publisher","first-page":"e237721","DOI":"10.1136\/bcr-2020-237721","article-title":"Nivolumab for malignant peritoneal mesothelioma","volume":"13","author":"Tanaka","year":"2020","journal-title":"BMJ Case Rep"},{"key":"key20250312100340_b25-ol-29-4-14933","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1016\/j.jtho.2016.07.033","article-title":"Malignant mesothelioma effusions are infiltrated by CD3+ T cells highly expressing PD-L1 and the PD-L1+ tumor cells within these effusions are susceptible to ADCC by the Anti-PD-L1 antibody avelumab","volume":"11","author":"Khanna","year":"2016","journal-title":"J Thorac Oncol"},{"key":"key20250312100340_b26-ol-29-4-14933","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1097\/JTO.0000000000000177","article-title":"B7-H1 expression in malignant pleural mesothelioma is associated with sarcomatoid histology and poor prognosis","volume":"9","author":"Mansfield","year":"2014","journal-title":"J Thorac Oncol"},{"key":"key20250312100340_b27-ol-29-4-14933","doi-asserted-by":"publisher","first-page":"e232526","DOI":"10.1001\/jamanetworkopen.2023.2526","article-title":"Clinical outcomes associated with pembrolizumab monotherapy among adults with diffuse malignant peritoneal mesothelioma","volume":"6","author":"Marmarelis","year":"2023","journal-title":"JAMA Netw Open"},{"key":"key20250312100340_b28-ol-29-4-14933","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.jss.2022.04.005","article-title":"Expression of PD-L1 in patients with malignant peritoneal mesothelioma: A pilot study","volume":"277","author":"Gazivoda","year":"2022","journal-title":"J Surg Res"},{"key":"key20250312100340_b29-ol-29-4-14933","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1016\/j.ejso.2017.05.009","article-title":"Immunohistochemical evaluation of two antibodies against PD-L1 and prognostic significance of PD-L1 expression in epithelioid peritoneal malignant mesothelioma: A RENAPE study","volume":"43","author":"Valmary-Degano","year":"2017","journal-title":"Eur J Surg Oncol"},{"key":"key20250312100340_b30-ol-29-4-14933","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1038\/s41416-020-01215-7","article-title":"Heterogeneity in PD-L1 expression in malignant peritoneal mesothelioma with systemic or intraperitoneal chemotherapy","volume":"124","author":"White","year":"2021","journal-title":"Br J Cancer"},{"key":"key20250312100340_b31-ol-29-4-14933","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","article-title":"Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin cisplatin pemetrexed study (MAPS): A randomised, controlled, open-label, phase 3 trial","volume":"387","author":"Zalcman","year":"2016","journal-title":"Lancet"},{"key":"key20250312100340_b32-ol-29-4-14933","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","article-title":"First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): A multicentre, randomised, open-label, phase 3 trial","volume":"397","author":"Baas","year":"2021","journal-title":"Lancet"},{"key":"key20250312100340_b33-ol-29-4-14933","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1080\/17843286.1989.11718015","article-title":"Autoimmune haemolytic anaemia associated with malignant peritoneal mesothelioma","volume":"44","author":"Selleslag","year":"1989","journal-title":"Acta Clin Belg"},{"key":"key20250312100340_b34-ol-29-4-14933","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/modpathol.3800245","article-title":"Granulocyte-colony stimulating factor- and interleukin 6-producing diffuse deciduoid peritoneal mesothelioma","volume":"18","author":"Kimura","year":"2005","journal-title":"Mod Pathol"},{"key":"key20250312100340_b35-ol-29-4-14933","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1007\/s00259-005-0059-1","article-title":"Malignant mesothelioma of the peritoneum as the cause of a paraneoplastic syndrome: Detection by 18F-FDG PET","volume":"33","author":"Banayan","year":"2006","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"key20250312100340_b36-ol-29-4-14933","first-page":"619348","article-title":"Recurrent thrombotic thrombocytopenic purpura-like syndrome as a paraneoplastic phenomenon in malignant peritoneal mesothelioma: A case report and review of the literature","volume":"2012","author":"Socola","year":"2012","journal-title":"Case Rep Oncol Med"},{"key":"key20250312100340_b37-ol-29-4-14933","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1182\/blood.2019003936","article-title":"Marked paraneoplastic leukemoid reaction in a patient with mesothelioma mimicking a myeloid neoplasm","volume":"135","author":"Thakral","year":"2020","journal-title":"Blood"},{"key":"key20250312100340_b38-ol-29-4-14933","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1631\/jzus.B1000338","article-title":"Malignant peritoneal mesothelioma presenting with persistent high fever","volume":"12","author":"Chen","year":"2011","journal-title":"J Zhejiang Univ Sci B"},{"key":"key20250312100340_b39-ol-29-4-14933","first-page":"596","article-title":"Fever of unknown origin: A clinical mask of malignant peritoneal mesothelioma","volume":"16","author":"Hermann","year":"2012","journal-title":"Contemp Oncol (Pozn)"},{"key":"key20250312100340_b40-ol-29-4-14933","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.radcr.2021.11.064","article-title":"Medical-type peritoneal mesothelioma leading to death two months after onset of fever of unknown origin","volume":"17","author":"Ishizuka","year":"2022","journal-title":"Radiol Case Rep"},{"key":"key20250312100340_b41-ol-29-4-14933","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1016\/S1470-2045(13)70381-4","article-title":"Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: An open-label, single-arm, phase 2 trial","volume":"14","author":"Calabr\u00f2","year":"2013","journal-title":"Lancet Oncol"},{"key":"key20250312100340_b42-ol-29-4-14933","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/S2213-2600(15)00092-2","article-title":"Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study","volume":"3","author":"Calabr\u00f2","year":"2015","journal-title":"Lancet Respir Med"},{"key":"key20250312100340_b43-ol-29-4-14933","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1016\/S1470-2045(17)30446-1","article-title":"Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): A multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial","volume":"18","author":"Maio","year":"2017","journal-title":"Lancet Oncol"},{"key":"key20250312100340_b44-ol-29-4-14933","doi-asserted-by":"publisher","first-page":"S8565","DOI":"10.1200\/JCO.2018.36.15_suppl.8565","article-title":"Phase II trial of pembrolizumab (P) in patients (pts) with previously-treated mesothelioma (MM)","volume":"36","author":"Desai","year":"2018","journal-title":"J Clin Oncol"},{"key":"key20250312100340_b45-ol-29-4-14933","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1001\/jamaoncol.2018.5428","article-title":"Efficacy and safety of avelumab treatment in patients with advanced unresectable mesothelioma: Phase 1b results from the JAVELIN solid tumor trial","volume":"5","author":"Hassan","year":"2019","journal-title":"JAMA Oncol"},{"key":"key20250312100340_b46-ol-29-4-14933","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1016\/S2213-2600(21)00043-6","article-title":"Tremelimumab plus durvalumab retreatment and 4-year outcomes in patients with mesothelioma: A follow-up of the open label, non-randomised, phase 2 NIBIT-MESO-1 study","volume":"9","author":"Calabr\u00f2","year":"2021","journal-title":"Lancet Respir Med"},{"key":"key20250312100340_b47-ol-29-4-14933","doi-asserted-by":"publisher","first-page":"e19956","DOI":"10.1097\/MD.0000000000019956","article-title":"Cisplatin plus pemetrexed therapy and subsequent immune checkpoint inhibitor administration for malignant peritoneal mesothelioma without pleural lesions: Case report","volume":"99","author":"Ikushima","year":"2020","journal-title":"Medicine (Baltimore)"},{"key":"key20250312100340_b48-ol-29-4-14933","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1186\/s12885-021-08025-x","article-title":"Efficacy of second-line treatment and prognostic factors in patients with advanced malignant peritoneal mesothelioma: A retrospective study","volume":"21","author":"Kitadai","year":"2021","journal-title":"BMC Cancer"},{"key":"key20250312100340_b49-ol-29-4-14933","doi-asserted-by":"publisher","first-page":"2738","DOI":"10.1158\/2159-8290.CD-21-0331","article-title":"Efficacy, safety, and biomarker analysis of combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) blockade in advanced malignant peritoneal mesothelioma","volume":"11","author":"Raghav","year":"2021","journal-title":"Cancer Discov"},{"key":"key20250312100340_b50-ol-29-4-14933","doi-asserted-by":"publisher","first-page":"e2119934","DOI":"10.1001\/jamanetworkopen.2021.19934","article-title":"Clinical efficacy of immune checkpoint inhibitors in patients with advanced malignant peritoneal mesothelioma","volume":"4","author":"Raghav","year":"2021","journal-title":"JAMA Netw Open"},{"key":"key20250312100340_b51-ol-29-4-14933","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1016\/S1470-2045(21)00471-X","article-title":"Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): A multicentre, double-blind, randomised, phase 3 trial","volume":"22","author":"Fennell","year":"2021","journal-title":"Lancet Oncol"},{"key":"key20250312100340_b52-ol-29-4-14933","doi-asserted-by":"publisher","first-page":"10317","DOI":"10.12998\/wjcc.v10.i28.10317","article-title":"Malignant peritoneal mesothelioma with massive ascites as the first symptom: A case report","volume":"10","author":"Huang","year":"2022","journal-title":"World J Clin Cases"},{"key":"key20250312100340_b53-ol-29-4-14933","doi-asserted-by":"publisher","first-page":"e703","DOI":"10.1093\/oncolo\/oyac099","article-title":"Phase I study of tremelimumab monotherapy or in combination with durvalumab in japanese patients with advanced solid tumors or malignant mesothelioma","volume":"27","author":"Fujiwara","year":"2022","journal-title":"Oncologist"},{"key":"key20250312100340_b54-ol-29-4-14933","doi-asserted-by":"publisher","first-page":"5296","DOI":"10.12998\/wjcc.v11.i22.5290","article-title":"Zimberelimab plus chemotherapy as the first-line treatment of malignant peritoneal mesothelioma: A case report and review of literature","volume":"11","author":"Peng","year":"2023","journal-title":"World J Clin Cases"},{"key":"key20250312100340_b55-ol-29-4-14933","doi-asserted-by":"publisher","first-page":"108359","DOI":"10.1016\/j.ijscr.2023.108359","article-title":"Response to Nivolumab followed by complete cytoreductive surgery with HIPEC resulted in long-term survival in a patient with sarcomatoid-predominant biphasic peritoneal mesothelioma. A case report","volume":"107","author":"Sugarbaker","year":"2023","journal-title":"Int J Surg Case Rep"},{"key":"key20250312100340_b56-ol-29-4-14933","first-page":"e43744","article-title":"Brain metastases with malignant peritoneal mesothelioma: Never reported before","volume":"15","author":"Lal","year":"2023","journal-title":"Cureus"}],"container-title":["Oncology Letters"],"original-title":[],"deposited":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T08:05:56Z","timestamp":1741766756000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/ol.2025.14933"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,13]]},"references-count":56,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,2,13]]}},"URL":"https:\/\/doi.org\/10.3892\/ol.2025.14933","relation":{},"ISSN":["1792-1074","1792-1082"],"issn-type":[{"type":"print","value":"1792-1074"},{"type":"electronic","value":"1792-1082"}],"subject":[],"published":{"date-parts":[[2025,2,13]]},"article-number":"187"}}